New drug combo shows promise for resistant ovarian cancer
NCT ID NCT03776812
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new drug called relacorilant combined with chemotherapy (nab-paclitaxel) in 178 women with ovarian, fallopian tube, or peritoneal cancer that came back and no longer responds to platinum-based treatments. The goal was to see if the combination helps keep the cancer from growing longer than chemotherapy alone. Participants received either the combination or chemotherapy only, and the study is now complete.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT FALLOPIAN TUBE CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Site Reference ID/Investigator #001
Chicago, Illinois, 60637, United States
-
Site Reference ID/Investigator #004
Birmingham, Alabama, 35249, United States
-
Site Reference ID/Investigator #032
Denver, Colorado, 80045, United States
-
Site Reference ID/Investigator #038
Scottsdale, Arizona, 85258, United States
-
Site Reference ID/Investigator #051
New York, New York, 10065, United States
-
Site Reference ID/Investigator #096
Montreal, Quebec, H2X 0A9, Canada
-
Site Reference ID/Investigator #106
Boston, Massachusetts, 02215, United States
-
Site Reference ID/Investigator #108
Leuven, 3000, Belgium
-
Site Reference ID/Investigator #109
Brussels, 1200, Belgium
-
Site Reference ID/Investigator #112
Naples, 80131, Italy
-
Site Reference ID/Investigator #113
Valencia, 46009, Spain
-
Site Reference ID/Investigator #114
Madrid, 28034, Spain
-
Site Reference ID/Investigator #115
Barcelona, 08035, Spain
-
Site Reference ID/Investigator #116
Madrid, 28034, Spain
-
Site Reference ID/Investigator #117
Toronto, Ontario, M4N 3M5, Canada
-
Site Reference ID/Investigator #119
Edegem, 2650, Belgium
-
Site Reference ID/Investigator #121
Milwaukee, Wisconsin, 53226, United States
-
Site Reference ID/Investigator #122
Milan, 20141, Italy
-
Site Reference ID/Investigator #124
Roma, 00168, Italy
-
Site Reference ID/Investigator #127
Pittsburgh, Pennsylvania, 15213, United States
-
Site Reference ID/Investigator #128
Boston, Massachusetts, 02215, United States
-
Site Reference ID/Investigator #135
Charlottesville, Virginia, 22908, United States
-
Site Reference ID/Investigator #169
New York, New York, 10065, United States
-
Site Reference ID/Investigator #170
New York, New York, 10065, United States